Minimal Residual Disease in AML

Why Has It Lagged Behind Pediatric ALL?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.

Original languageEnglish (US)
Article number548
Pages (from-to)S2-S6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue numberS
DOIs
StatePublished - Jun 1 2015

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Pediatrics
Therapeutics

Keywords

  • Acute leukemias
  • MRD
  • Response definition

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Minimal Residual Disease in AML : Why Has It Lagged Behind Pediatric ALL? / Paietta, Elisabeth M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. S, 548, 01.06.2015, p. S2-S6.

Research output: Contribution to journalArticle

@article{7331048e8507439b8ec08888655120c4,
title = "Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?",
abstract = "Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.",
keywords = "Acute leukemias, MRD, Response definition",
author = "Paietta, {Elisabeth M.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.clml.2015.02.009",
language = "English (US)",
volume = "15",
pages = "S2--S6",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "S",

}

TY - JOUR

T1 - Minimal Residual Disease in AML

T2 - Why Has It Lagged Behind Pediatric ALL?

AU - Paietta, Elisabeth M.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.

AB - Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.

KW - Acute leukemias

KW - MRD

KW - Response definition

UR - http://www.scopus.com/inward/record.url?scp=84939629912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939629912&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2015.02.009

DO - 10.1016/j.clml.2015.02.009

M3 - Article

VL - 15

SP - S2-S6

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - S

M1 - 548

ER -